Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Gynecologic 3Head & Neck 2Gastrointestinal 2Breast 2CNS 1

Conditions

Ovarian Neoplasms 178Endometrial Neoplasms 110Uterine Cervical Neoplasms 100Breast Neoplasms 58Colorectal Neoplasms 49Fallopian Tube Neoplasms 45Carcinoma, Non-Small-Cell Lung 42Neoplasms 36Pancreatic Neoplasms 34Prostatic Neoplasms 27Neoplasm Metastasis 27Stomach Neoplasms 25Melanoma 25Squamous Cell Carcinoma of Head and Neck 22Lung Neoplasms 22Esophageal Neoplasms 21Carcinoma, Ovarian Epithelial 20Triple Negative Breast Neoplasms 19Carcinoma, Renal Cell 18Urinary Bladder Neoplasms 17Head and Neck Neoplasms 17Colonic Neoplasms 16Carcinoma, Transitional Cell 16Carcinoma, Hepatocellular 15Small Cell Lung Carcinoma 14Sarcoma 14Cholangiocarcinoma 14Uterine Neoplasms 13Vulvar Neoplasms 12Rectal Neoplasms 12

Interventions

Fulvestrant 2ribociclib 1palbociclib 1niraparib 1exemestane 1abemaciclib 1Tamoxifen 1STX-478 1Metformin 1Letrozole 1Imlunestrant 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Hereditary Sensory and Autonomic Neuropathies × Gynecologic × 30 days × Clear all
NCT05768139 2026-06-04

PIKALO-1

Eli Lilly and Company

Phase 1/2 Recruiting
880 enrolled
BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT06433219 2026-06-03

Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

EMD Serono

Phase 2 Active not recruiting
63 enrolled
Gynecologic

Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms

NCT06993844 2026-05-06

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

Ensem Therapeutics

Phase 1/2 Recruiting
233 enrolled
BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡